Arecor Therapeutics and Skye Bioscience have agreed a formulation development collaboration to develop a novel, higher concentration formulation of Skye’s CB1 inhibitor, nimacimab. Skye is evaluating nimacimab, a first-in-class CB1-inhibiting monoclonal antibody, in its Phase IIa CBeyond clinical trial in patients with obesity and overweight. Data from… Read More
Skye Bioscience has announced preliminary data from a diet-induced obesity (DIO) model in mice, in which its CB1-inhibiting antibody, nimacimab, achieved dose-dependent weight loss of up to 16% compared to vehicle. Skye developed a DIO model using a transgenic mouse expressing the human CB1 receptor… Read More
Skye Bioscience has started screening patients for a Phase II clinical trial (CBeyond) of its novel peripheral CB1 inhibitor, nimacimab, a negative allosteric modulating antibody. The study will assess the ability of nimacimab as a next-generation weight loss therapeutic to safely and effectively reduce weight in… Read More
